Skip to content

Apyx Medical Corporation APYX Accrued Progress Collections and Price Adjustments

Other financials

Income statement

See full
Revenue$12.5M+32.4%
Gross profit$7.5M-19.2%
Operating income-$5.5M-349%
Net income-$2.1M+48.6%
EPS (diluted)-$0.19-533%

Balance sheet

See full
Cash & equivalents$31.1M+0.4%
Total debt$39.5M+1.4%
Total equity$12.8M+22.1%
Total assets$63.0M+4.8%

Cash flow

See full
Operating cash flow-$572.0K+18.5%
CapEx$60.0K+9.1%
Free cash flow-$632.0K+16.5%

Valuation

See full
Market cap$181.07M+114%
Enterprise value$189.4M+101%
P/S3.2×+1.4×

Profitability

See full
Gross margin61.9%-3.1pp
Operating margin-46%+9.9pp
Net margin-16.2%-6.2pp
FCF margin-16.1%-4.8pp

Returns & leverage

See full
Return on equity-77.8%-22.4pp
Debt / equity3.1×-0.6×
Current ratio5.8×+0.3×

Where this comes from

Reported directly by Apyx Medical Corporation in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Apyx Medical Corporation’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apyx Medical Corporation's accrued progress collections and price adjustments.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Apyx Medical Corporation's accrued progress collections and price adjustments?
Apyx Medical Corporation (APYX) reported accrued progress collections and price adjustments of $1.13M in Q1 2026.
How has Apyx Medical Corporation's accrued progress collections and price adjustments changed year-over-year?
Apyx Medical Corporation's accrued progress collections and price adjustments decreased by 5.3% year-over-year, from $1.19M to $1.13M.
What is the long-term trend for Apyx Medical Corporation's accrued progress collections and price adjustments?
Over 5 years (2020 to 2025), Apyx Medical Corporation's accrued progress collections and price adjustments has grown at a 11.1% compound annual growth rate (CAGR), from $621K to $1.05M.